Bridging animal health and diagnosis
Through unrivaled technology
  • 1
  • 3
Core technology
Ceaseless challenges and changes
Innovative bio-technology
  • 2
  • 3
Bio-contents
Solution Partner for Healthy
Coexistence of Humans and Animals
  • 3
  • 3
Global leader
    PRODUCT Introducing BIONOTE’s Products.
    • Rapid Immunoassay
      Rapid
    • Fluorescence Immunoassay
      Vcheck F
    • Enzyme Immunoassay
      ELISA
    • Molecular Diagnostics
      Vcheck M
    • Biochemistry
      Vcheck C
    NEWS Stay in the know of the latest Bionote updates. More
    Bionote receives approval from MAFF Japan for sale of kindey disease diagnostic kit... "Will provide to 3,000 Japanese animal hospitals from next year onwards"

     DISCLAIMER: This news article is a direct translation of the original Korean article from The Stock. BioNote Inc. does not claim any right to the article or claim any ownership.The translation was completed by BioNote Inc. only for the convenience of non-Korean speaking customers and BioNote Inc. does not seek to redistribute nor acquire profit from the translation.​Bionote, an in vitro diagnostic product manufacturer, announced they have completed the Japanses MAFF approval process for their 'Vcheck SDMA' kit, which is used for early screening of decreased kidney function in companion animals. Through this approval, it has become possible for Bionote to sell the 'Vcheck SDMA' kits in Japan, and Bionote has announced they will start providing it through their local Japanese partners.SDMA (Symmetric Dimethylarginine), is a amino acid that is produced during the process of breaking down proteins in the body and 90% of it is filtered by the kidney. If the kidney is not functioning properly, the SDMA does not get filtered out of the system and remains in the body. An IVD kit can be used to measure the SDMA levels in the body to screen for decreased kidney function and SDMA has less interfering factors than traditional biomarkers, with SDMA levels increasing after only 25 - 40% of damage to the kidneys.Traditional biomarkers that are used to test for kidney function, such as creatinine, is affected by factors such as whether the cat or dog in question has a lot of muscle mass and only starts to increase after around 75% of the kidney has been damaged. As such, in recent years, SDMA tests have been used more frequently for early screening of chronic kidney diseases, according to Bionote.Bionote's 'Vcheck SDMA' diagnostic kit quantitavely measures the SDMA amount in samples, using an analyzer called Vcheck F V200, quickly and with ease. Bionote also explained that when the Vcheck SDMA results were compared with lab tests, 98% of the results were in agreement. The kit only requires 100 microliters of serum or plasma (heparin) samples and the results can be confirmed after only 11 minutes, said the Bionote spokesperson.CEO of Bionote, Dr. Byung Ki Cho, said that "it has become possible for us to sell our Vcheck SDMA in Japan through this approval and registration" and that "We expect to be able to provide this product to over 3,000 animal hospitals in Japan from 2023 onwards". Bionote is currently in the process of going public in KOSPI through NH Investment & Securities and Korea Investment & Securities, at the end of the year.Link to original article: https://www.the-stock.kr/news/articleView.html?idxno=17476

    2022.12.01
    BIONOTE attends MEDICA, the biggest medical diagnostic exhibition in the world

     Global leader in providing biological raw materials and animal diagnostics company BIONOTE, participated in the biggest medical diagnostic exhibition in the world, MEDICA, which took place on the 14th to 18th of November in Düsseldorf, Germany.  MEDICA is a exhibition that has been taking place at Messe Düsseldorf GmbH for over 40 years and is known as the biggest exhibition in Europe for the medical diagnostic field. Even during the height of the COVID-19 pandemic last year, over 3,500 companies from 66 countries participated with 150,000 visitors from 150 countries visiting. Messe Düsseldorf has 17 halls for exhibitions, each hall for a different category of the medical field. The categories include IVD kits, diagnostic imaging, lab equipments, amongst many others. This is the first time that BIONOTE has participated in the MEDICA exhibition and they introduced their newly released Vcheck M, cutting edge POC PCR analyzer, as well as their main products, Rapid Diagnostic kits, Vcheck F and  ELISA diagnostic kits. Furthermore, they also introduced their Vcheck C, a clinical chemistry analyzer, which will be released in the first quarter of 2023. By participating in the exhibition, BIONOTE was able to introduce their excellent product concepts and future market strategies for future products, to visitors from all over the world, and to raise awareness of BIONOTE. It was a successful exhibition in terms of confirming BIONOTE's potential as a global total diagnostic solution provider.

    2022.11.24
    BIONOTE participates in Gyeonggi Veterinary Conference

    Global leader in providing biological raw materials and animal diagnostics company BIONOTE, participated in Gyeonggi Veterinary Conference on the 13th of November in Suwon Convention Center. Gyeonggi Veterinary Conference is an annual conference hosted by the Geyonggi Veterinary Medicine Association where approximately 2,000 veterinarians participate in order to discuss the latest trends and to elevate clinical technology to the next level. Internal medicine, surgery, feline diagnostics are a few of the many different categories of seminars held during the conference and companies that provide medical/diagnostic equipments, medical/diagnostic reagents and distributors participated in the exhibition that is a part of the conference. BIONOTE showcased their latest products such as the Vcheck M, POC PCR analyzer, as well as their Vcheck C, clinical chemistry analyzer, which will be released in the first quarter of 2023, along with their main popular products such as rapid diagnostic kits, Vcheck F and ELISA kits. Furthermore, they gave out free samples of their Vcheck F Feline TnI kit, which can be used to screen for feline heart diseases and screen for feline heart damage, to the visitors of their booth to celebrate the fact that it received the liscence for domestic sales.Through the conference, BIONOTE was able to communicate directly with its customers and receive meaningful feedback, especially regarding the new products, with the great interest shown by the visitors. 

    2022.11.24
    Bionote Receives Certificate of Free Sales for Feline Rapid Diagnostic Kit... "Immunodeficiency Virus test results in just 15 minutes"

    DISCLAIMER: This news article is a direct translation of the original Korean article from MoneyToday. BioNote Inc. does not claim any right to the article or claim any ownership.The translation was completed by BioNote Inc. only for the convenience of non-Korean speaking customers and BioNote Inc. does not seek to redistribute nor acquire profit from the translation. 'FIV Ab/FeLV Ag 2.0' Rapid diagnostic kit that measures the presence of Feline Immunodeficiency Virus and Feline Leukemia Virus is set to enter the 5.3 billion USD worth global pet diagnostic market Bionote announced on the 10th that they have received the Certificate of Free Sales ("CFS") from the Korea Animal and Plant Quarantine Agency for their 'FIV Ab/FeLV Ag 2.0' kit which can test the presence of Feline Immunodeficiency Virus and Feline Leukemia Virus with one kit. Through the CFS, Bionote has acquired the chance to target the global market as well as the domestic market. The pet diagnostic market is estimates to be worth 5.3 billion USD this year. A Bionote spokesperson commented that "The biggest advantage of this new product is that the user is able to screen for the viruses with just a small amount of blood as sample, taking only 15 minutes" and that "By upgrading to version 2.0 from the original kit, we were able to reduce the number of samples required for the test, from two of the same sample to just one sample, making the test process more convenient for the user". Feline Immunodeficiency Virus (FIV) is a retrovirus that destroys a cat's immune system. It affects all animals in the cat family, and it's said around 2.5 - 4.4% of cats worldwide are infected. Routine testing for FIV seems to be needed because, depending on the region, around 1~14% of healthy cats is said to have tested positive for FIV antibodies and around 44% of unhealthy cats is said to have tested positive for FIV antibodies.  Feline Leukemia Virus (FeLV) is a retrovirus that weakens a cat's immune system. FeLV is divided into 4 subgroups; A, B, C, T and it's said to have infected between 2.5 - 7.5 % of cats in North America. Of the two viruses, FIV is typically not fatal to cats, but as time passes, the virus will weaken the immune system of the cat, and this may lead to fatal secondary infection. FeLV is not fatal to cats as well, but it reduces the life expectancy of cats and is easily transmitted between cats, meaning FeLV positive cats must be quarantined with other FeLV positive cats. Link: https://news.mt.co.kr/mtview.php?no=2022111013352912335 

    2022.11.11
    Bionote "Enters the global market with POCT PCR device M10"

    DISCLAIMER: This news article is a direct translation of the original Korean article from eDaily. BioNote Inc. does not claim any right to the article or claim any ownership.The translation was completed by BioNote Inc. only for the convenience of non-Korean speaking customers and BioNote Inc. does not seek to redistribute nor acquire profit from the translation.  [E-Daily Reporter Seok Ji-heon] Bionote, a global leading company in bio content and animal diagnosis, announced on the 2nd that the " state-of-the-art field molecular diagnostic equipment Vcheck M10 (hereinafter, M10)", which was recently introduced in overseas markets. M10 received favorable reviews at the 2022 World Small Animal Veterinary Association (WSAVA). The event was held in Lima, Peru from the 29th to the 31st of last month.  "We once again confirmed the possibility of success in the global market due to the M10 products' innovative technology," a Bionote official said. "Bionote, which has previously shown expertise in immunodiagnosis, will become a global leader in providing total solutions from initial screening to PCR confirmation."M10 is an automated device that integrates nucleic acid extraction and nucleic acid amplification (PCR) into one device, which was previously carried out by separate equipments. M10 has a very simple inspection process, so using this equipment, veterinarians at general veterinary hospitals can conduct PCR tests at animal hospitals without additional training. The company explained that this is groundbreaking because it can quickly and accurately perform PCR confirmation tests at the field in an hour, which was requested by a professional inspection agency, which took about 1 to 3 days.M10 equipment has completed the export license of the quarantine headquarters and the European CE certification, and is preparing for domestic use. As a cartridge used in M10 equipment, "Vcheck MEhrlichia/Anaplasma" was launched overseas for the first time in September this year, and "Vcheck M Babesia gibsoni/canis" was developed as the second item and is being prepared for overseas launch in November. Cartridges that can test up to eight types of animal diseases at a time will also be introduced within this year.Meanwhile, Bionote is seeking to be listed on the KOSPI within this year to accelerate global growth.Link: https://pharm.edaily.co.kr/news/read?newsId=01443206632521784&mediaCodeNo=257 

    2022.11.03
    Bionote's 'Vcheck M10' POCT PCR device is highly rated overseas

     DISCLAIMER: This news article is a direct translation of the original Korean article from Getnews. BioNote Inc. does not claim any right to the article or claim any ownership.The translation was completed by BioNote Inc. only for the convenience of non-Korean speaking customers and BioNote Inc. does not seek to redistribute nor acquire profit from the translation.    BioNotes (CEO Cho Byung-ki), a global leading bio-content and animal diagnosis company, recently launched overseas, announced on the 2nd that its cutting-edge field molecular diagnostic equipment Vcheck M10 (hereinafter M10) received favorable reviews for its technology at the 2022 World Small Animal Society (WSAVA) Congress.The event was held in Lima, Peru from the 29th to the 31st of last month, and received high attention from veterinarians and veterinary diagnostic industry officials around the world for its M10 product's innovative technology, according to BioNote.M10 is an automated device that integrates nucleic acid extraction and nucleic acid amplification (PCR) into one device, which was previously carried out by separate equipments. The M10 has a very simple inspection process, so using this equipment, veterinarians at general veterinary hospitals can conduct PCR tests at animal hospitals without additional training. This is groundbreaking because the PCR confirmation test, which was requested by a professional inspection agency, which took about 1 to 3 days, can be carried out quickly and accurately at field in an hour.M10 has completed the export license of the quarantine headquarters and the European CE certification, and is preparing for domestic use. As a cartridge used in M10 equipment, "Vcheck MEhrlichia/Anaplasma" was launched overseas for the first time in September this year, and "Vcheck M Babesia gibsoni/canis" was developed as the second item and is being prepared for overseas launch in November.BioNote said, "We have confirmed the market's great demand for M10 through the Vcheck M launch show and 2022 WSAVA in Latin America," adding, "BioNote, which has previously shown expertise in immunodiagnosis, aims to become a global leading company that provides total solutions from initial screening tests to PCR confirmation tests."Source : Getnews (http://www.getnews.co.kr) Article Link: https://www.getnews.co.kr/news/articleView.html?idxno=604367

    2022.11.03

    An era of PCR test at local veterinary is about to begin.  On the 28th of September, Bionote Inc. representative stated, “Last September, we have released Vcheck M10(Hereinafter, M10) overseas, a cutting-edge Point-of-care testing(POCT) PCR device.” Adding, we are in preparation of domestic permission for use.” M10 is a device that can perform both nucleic acid extraction and amplification with just a single device. Due to simplified test process, any veterinary can run PCR test without a special training. In addition, tests that conventionally required minimum of 1~3days at a specialized veterinary laboratory can now be done in an hour with M10. M10 has been sent to Korea’s domestic veterinary universities and overseas testing facilities in various countries (United States, Spain, Poland, Australia, etc) for product assessment. This product is expected to be highly anticipated by the market along with Bionote’s world-known fluorescent immune equipment Vcheck F series (V200, V2400) M10 is CE approved and has achieved export license by the KAPQA(Korea Animal and Plant Quarantine Agency) and domestic permission for use is currently in preparation. Last September, Bionote released the first of M10’s product line Vcheck M Ehrlichia/Anaplasma overseas. Second item, Vcheck M Babesia gibsoni/canis will be launched overseas this coming November. Along with the two products, they are currently in development of an item that could test 8 multiple pathogens with a single cartridge, which could change the dynamics of the veterinary market. Bionote Inc. stated, “Our company looks to expand our field of market by adding molecular diagnostics product Vcheck M along with other product lines(RDT, ELISA, fluorescence immunoassay). With this effort we hope to become a global leader by providing a total diagnostics solution, starting from early screening test to confirmatory test.”You can refer to Bionote’s official number (+82-031-211-0516) to get detailed information on Vcheck M10 and other product line. 

    2022.10.31
    Bionote Participates in the Largest Veterinary Conference in the Yeongnam Region

      Bionote participated in the 12th Yeongnam Veterinary Conference held at Changwon Convention Center from July 23rd to 24th. As the largest veterinary conference in the Yeongnam region, it is also considered one of the top three veterinary conferences held in Korea.  Due to COVID-19, the Yeongnam Veterinary Conference has been held online for the year 2020 and 2021. This is the first time in three years that it has finally been held as an in-person event. The theme for the 12th conference was ‘Back to Basic’, with 31 lecturers on various topics such as internal medicine, dentistry, skin, and cardiac.  Despite the spread of COVID-19, more than 1,000 veterinarians and veterinary school students visited the conference. Bionote also participated in the conference through booth operation, focusing on promoting the Feline TnI, which will soon be launched in the following August. There was also a free sample giveaway which was met with high consumer demand. Feline TnI is a test marker for a quantitative measurement of Troponin I in feline serum and can be used on Bionote’s immunofluorescence analyzer Vcheck F series. This marker is especially useful for screening hypertrophic cardiomyopathy (HCM), which is a common cardiac disease in cats. As with its largest installation share in the Korean veterinary market, many of the Vcheck F users have visited the Bionote booth and showed great interest in the soon-to-be-launched product.  Bionote plans to participate in additional conferences in Busan and Seoul and will continue to communicate with its customers throughout.

    2022.08.02